- Home
- GGR vs KPTI Comparison
GGR vs KPTI Comparison
Compare GGR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- KPTI
- Stock Information
- Founded
- GGR 2011
- KPTI 2008
- Country
- GGR Taiwan
- KPTI United States
- Employees
- GGR N/A
- KPTI N/A
- Industry
- GGR Auto Manufacturing
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- GGR Consumer Discretionary
- KPTI Health Care
- Exchange
- GGR Nasdaq
- KPTI Nasdaq
- Market Cap
- GGR 88.6M
- KPTI 102.4M
- IPO Year
- GGR N/A
- KPTI 2013
- Fundamental
- Price
- GGR $3.73
- KPTI $5.62
- Analyst Decision
- GGR
- KPTI Strong Buy
- Analyst Count
- GGR 0
- KPTI 6
- Target Price
- GGR N/A
- KPTI $22.17
- AVG Volume (30 Days)
- GGR 18.7K
- KPTI 111.5K
- Earning Date
- GGR 11-11-2025
- KPTI 11-03-2025
- Dividend Yield
- GGR N/A
- KPTI N/A
- EPS Growth
- GGR N/A
- KPTI N/A
- EPS
- GGR N/A
- KPTI N/A
- Revenue
- GGR $280,211,000.00
- KPTI $142,530,000.00
- Revenue This Year
- GGR N/A
- KPTI $4.87
- Revenue Next Year
- GGR $5.00
- KPTI $9.20
- P/E Ratio
- GGR N/A
- KPTI N/A
- Revenue Growth
- GGR N/A
- KPTI N/A
- 52 Week Low
- GGR $3.55
- KPTI $3.51
- 52 Week High
- GGR $13.99
- KPTI $13.20
- Technical
- Relative Strength Index (RSI)
- GGR 57.20
- KPTI 45.34
- Support Level
- GGR $3.69
- KPTI $5.31
- Resistance Level
- GGR $4.05
- KPTI $6.50
- Average True Range (ATR)
- GGR 0.27
- KPTI 0.41
- MACD
- GGR -0.05
- KPTI 0.00
- Stochastic Oscillator
- GGR 56.00
- KPTI 36.25
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.